Annals of Surgical Oncology

, Volume 20, Supplement 3, pp 450–458 | Cite as

HPV Status of Oropharyngeal Cancer by Combination HPV DNA/p16 Testing: Biological Relevance of Discordant Results

  • Angela Hong
  • Deanna Jones
  • Mark Chatfield
  • C. Soon Lee
  • Mei Zhang
  • Jonathan Clark
  • Michael Elliott
  • Gerald Harnett
  • Christopher Milross
  • Barbara Rose
Translational Research and Biomarkers

Abstract

Background and Purpose

Human papillomavirus (HPV) causes up to 70 % of oropharyngeal cancers (OSCC). HPV positive OSCC has a more favorable outcome, thus HPV status is being used to guide treatment and predict outcome. Combination HPV DNA/p16ink4 (p16) testing is commonly used for HPV status, but there are no standardized methods, scoring or interpretative criteria. The significance of discordant (HPV DNA positive/p16 negative and HPV DNA negative/p16 positive) cancers is controversial. In this study, 647 OSCCs from 10 Australian centers were tested for HPV DNA/p16 expression. Our aims are to determine p16 distribution by HPV DNA status to inform decisions on p16 scoring and to assess clinical significance of discordant cancers.

Methods

HPV DNA was identified using a multiplex tandem HPV E6 polymerase chain reaction (PCR) assay and p16 expression by semiquantitative immunohistochemistry.

Results

p16 distribution was essentially bimodal (42 % of cancers had ≥70 % positive staining, 52 % <5 % positive, 6 % between 5 and 70 %). Cancers with 5 to <50 % staining had similar characteristics to the p16 negative group, and cancers with 50 to <70 % staining were consistent with the ≥70 % group. Using a p16 cut-point of 50 %, there were 25 % HPV DNA positive/p16 negative cancers and 1 % HPV DNA negative/p16 positive cancers. HPV DNA positive/p16 negative cancers had outcomes similar to HPV DNA negative/p16 negative cancers.

Conclusions

50 % is a reasonable cut-point for p16; HPV DNA positive/p16 negative OSCCs may be treated as HPV negative for clinical purposes; HPV DNA/p16 testing may add no prognostic information over p16 alone.

Supplementary material

10434_2012_2778_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 20 kb)

References

  1. 1.
    Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008; 1006:407–20.CrossRefGoogle Scholar
  2. 2.
    D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 35619:1944–56.CrossRefGoogle Scholar
  3. 3.
    Li W, Thompson CH, O’Brien CJ, et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer. 2003 Sep 10;106(4):553–8.Google Scholar
  4. 4.
    Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008; 1004:261–9.CrossRefGoogle Scholar
  5. 5.
    Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009; 2712:1992–8.CrossRefGoogle Scholar
  6. 6.
    Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 3631:24–35.CrossRefGoogle Scholar
  7. 7.
    Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006; 2436:5630–6.CrossRefGoogle Scholar
  8. 8.
    Fischer CA, Kampmann M, Zlobec I, et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol. 2010; 2110:1961–6.CrossRefGoogle Scholar
  9. 9.
    Hong AM, Dobbins TA, Lee CS, et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer. 2010; 10310:1510–7.CrossRefGoogle Scholar
  10. 10.
    Lewis JS, Jr., Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010; 348:1088–96.CrossRefGoogle Scholar
  11. 11.
    Lukas J, Muller H, Bartkova J, et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell’s requirement for cyclin D1 function in G1. J Cell Biol. 1994 May;125(3):625–38.PubMedCrossRefGoogle Scholar
  12. 12.
    Hoffmann M, Ihloff AS, Gorogh T, et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer. 2010; 1277:1595–602.CrossRefGoogle Scholar
  13. 13.
    Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010; 2827:4142–8.CrossRefGoogle Scholar
  14. 14.
    Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006; 245:736–47.CrossRefGoogle Scholar
  15. 15.
    Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007; 12111:2465–72.CrossRefGoogle Scholar
  16. 16.
    Begum S, Gillison ML, Ansari-Lari MA, et al. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res. 2003; 917:6469–75.Google Scholar
  17. 17.
    Klussmann JP, Gultekin E, Weissenborn SJ, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003; 1623:747–53.CrossRefGoogle Scholar
  18. 18.
    Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer. 2008; 12212:2656–64.CrossRefGoogle Scholar
  19. 19.
    Smeets SJ, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene. 2006; 2517:2558–64.CrossRefGoogle Scholar
  20. 20.
    Jung AC, Briolat J, Millon R, et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer. 2010; 1268:1882–94.Google Scholar
  21. 21.
    Junor E, Kerr G, Oniscu A, et al. Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. Br J Cancer. 2011.Google Scholar
  22. 22.
    .Perrone F, Gloghini A, Cortelazzi B, et al. Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. Am J Surg Pathol. 2011; 355:774–7; author reply 777–8.Google Scholar
  23. 23.
    Barnes L, Eveso JW, Reichert P, Sidransky D. WHO Classisification of Tumours: Pathology & Genetics of Head & Neck Tumours. Lyon: IARC, 2005. pp. 118–121.Google Scholar
  24. 24.
    Hong AM, Martin A, Armstrong BK, et al. Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol. 2012.Google Scholar
  25. 25.
    Stanley KK, Szewczuk E. Multiplexed tandem PCR: gene profiling from small amounts of RNA using SYBR Green detection. Nucleic Acids Res. 2005; 3320:e180.CrossRefGoogle Scholar
  26. 26.
    Hong A, Dobbins T, Lee CS, et al. Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur J Cancer. 2010; 4611:2088–96.CrossRefGoogle Scholar
  27. 27.
    Hong AM, Dobbins TA, Lee CS, et al. Use of cyclin D1 in conjunction with human papillomavirus status to predict outcome in oropharyngeal cancer. Int J Cancer. 2011; 1287:1532–45.CrossRefGoogle Scholar
  28. 28.
    van den Broek GB, Wildeman M, Rasch CR, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer. 2009; 12411:2643–50.CrossRefGoogle Scholar
  29. 29.
    Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998; 1536:1741–8.CrossRefGoogle Scholar
  30. 30.
    Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA. 1999; 9622:12754–9.CrossRefGoogle Scholar
  31. 31.
    Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996; 5616:3630–3.Google Scholar
  32. 32.
    Klingenberg B, Hafkamp HC, Haesevoets A, et al. p16 INK4A overexpression is frequently detected in tumour-free tonsil tissue without association with HPV. Histopathology. 2010; 567:957–67.CrossRefGoogle Scholar
  33. 33.
    Wiest T, Schwarz E, Enders C, et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene. 2002; 2110:1510–7.CrossRefGoogle Scholar
  34. 34.
    Weinberger PM, Yu Z, Kountourakis P, et al. Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: validation of three-class hypothesis. Otolaryngol Head Neck Surg. 2009; 1413:382–9.CrossRefGoogle Scholar
  35. 35.
    Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004; 9613:998–1006.CrossRefGoogle Scholar
  36. 36.
    Robinson M, Sloan P, Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol. 2010; 467:492–6.CrossRefGoogle Scholar
  37. 37.
    Begum S, Cao D, Gillison M, et al. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res. 2005; 1116:5694–9.CrossRefGoogle Scholar
  38. 38.
    Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010; 1169:2166–73.Google Scholar
  39. 39.
    Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 4367051:720–4.CrossRefGoogle Scholar
  40. 40.
    Castillo JP, Kowalik TF. Human cytomegalovirus immediate early proteins and cell growth control. Gene. 2002; 2901-2:19–34.CrossRefGoogle Scholar
  41. 41.
    .Helt AM, Galloway DA. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis. 2003; 242:159–69.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Angela Hong
    • 1
    • 2
  • Deanna Jones
    • 3
  • Mark Chatfield
    • 4
  • C. Soon Lee
    • 5
    • 6
    • 7
  • Mei Zhang
    • 1
    • 2
    • 3
  • Jonathan Clark
    • 8
  • Michael Elliott
    • 2
    • 8
  • Gerald Harnett
    • 9
  • Christopher Milross
    • 1
    • 2
  • Barbara Rose
    • 3
    • 8
  1. 1.Department of Radiation OncologyRoyal Prince Alfred HospitalSydneyAustralia
  2. 2.Sydney Medical SchoolThe University of SydneySydneyAustralia
  3. 3.Department of Infectious Diseases and Immunology, Central Clinical SchoolThe University of SydneySydneyAustralia
  4. 4.NHMRC Clinical Trials CentreThe University of SydneySydneyAustralia
  5. 5.Discipline of Pathology, School of MedicineUniversity of Western SydneySydneyAustralia
  6. 6.Department of Anatomical PathologyLiverpool HospitalSydneyAustralia
  7. 7.Cancer Pathology, Bosch Institute, The University of Sydney and Dept of Anatomical PathologyRoyal Prince Alfred HospitalSydneyAustralia
  8. 8.Sydney Head and Neck Cancer InstituteRoyal Prince Alfred HospitalSydneyAustralia
  9. 9.Pathwest Laboratory MedicineQEII Medical CentreNedlands, PerthAustralia

Personalised recommendations